36 related articles for article (PubMed ID: 33550024)
1. Immunological and hematological findings as major features in a patient with a new germline pathogenic CBL variant.
Stellacci E; Carter JN; Pannone L; Stevenson D; Moslehi D; Venanzi S; ; Bernstein JA; Tartaglia M; Martinelli S
Am J Med Genet A; 2024 Apr; ():e63627. PubMed ID: 38613168
[TBL] [Abstract][Full Text] [Related]
2. Case report: A safeguard in the sea of variants of uncertain significance: a case study on child with high risk neuroblastoma and acute myeloid leukemia.
Fabozzi F; Carrozzo R; Lodi M; Di Giannatale A; Cipri S; Rosignoli C; Giovannoni I; Stracuzzi A; Rizza T; Montante C; Agolini E; Di Nottia M; Galaverna F; Del Baldo G; Del Bufalo F; Mastronuzzi A; De Ioris MA
Front Oncol; 2023; 13():1324013. PubMed ID: 38260858
[TBL] [Abstract][Full Text] [Related]
3. Cancer variant modeling in vivo.
Istadi A; Porazinski S; Pajic M
Nat Biotechnol; 2024 Mar; 42(3):383-385. PubMed ID: 38123743
[No Abstract] [Full Text] [Related]
4. Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1).
Fisher MJ; Jones DTW; Li Y; Guo X; Sonawane PS; Waanders AJ; Phillips JJ; Weiss WA; Resnick AC; Gosline S; Banerjee J; Guinney J; Gnekow A; Kandels D; Foreman NK; Korshunov A; Ryzhova M; Massimi L; Gururangan S; Kieran MW; Wang Z; Fouladi M; Sato M; Øra I; Holm S; Markham SJ; Beck P; Jäger N; Wittmann A; Sommerkamp AC; Sahm F; Pfister SM; Gutmann DH
Acta Neuropathol; 2021 Apr; 141(4):605-617. PubMed ID: 33585982
[TBL] [Abstract][Full Text] [Related]
5. Systematic identification of non-coding somatic single nucleotide variants associated with altered transcription and DNA methylation in adult and pediatric cancers.
Chen F; Zhang Y; Creighton CJ
NAR Cancer; 2021 Mar; 3(1):zcab001. PubMed ID: 33554123
[TBL] [Abstract][Full Text] [Related]
6. Somatic CBL mutation presenting as juvenile myelomonocytic leukemia with vasculitis.
Mishra V; Krishnan VP; Desai M; Manek H; Pandrowala A; Bodhanwala M; Hiwarkar P
Pediatr Blood Cancer; 2023 Jun; 70(6):e30252. PubMed ID: 36786373
[No Abstract] [Full Text] [Related]
7. Pro-prion, as a membrane adaptor protein for E3 ligase c-Cbl, facilitates the ubiquitination of IGF-1R, promoting melanoma metastasis.
Li H; Zhang J; Ke JR; Yu Z; Shi R; Gao SS; Li JF; Gao ZX; Ke CS; Han HX; Xu J; Leng Q; Wu GR; Li Y; Tao L; Zhang X; Sy MS; Li C
Cell Rep; 2022 Dec; 41(12):111834. PubMed ID: 36543142
[TBL] [Abstract][Full Text] [Related]
8. Morphologic and Immunophenotypic Differences in Juvenile Myelomonocytic Leukemias With CBL and Other Canonical RAS-pathway Gene Mutations: A Single Institutional Experience.
Mariani RA; Jennings L; Zhang S; Bhat R; Gong S
J Pediatr Hematol Oncol; 2021 Aug; 43(6):e819-e825. PubMed ID: 33769390
[TBL] [Abstract][Full Text] [Related]
9. Statistical Mechanics Metrics in Pairing and Parsing In Silico and Phenotypic Data of a Novel Genetic NFκB1 (c.T638A) Variant.
Chaudhri EN; Abbott JM; Islam NN; Weber CA; Coban MA; Bilgili A; Squire JD; Mantia S; Wierenga KJ; Caulfield TR
Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895204
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic screening models for rapid diagnosis of genetic variants and discovery of personalized therapeutics.
Hopkins CE; Brock T; Caulfield TR; Bainbridge M
Mol Aspects Med; 2023 Jun; 91():101153. PubMed ID: 36411139
[TBL] [Abstract][Full Text] [Related]
11. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
[TBL] [Abstract][Full Text] [Related]
12. Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms.
Ogawa S; Shih LY; Suzuki T; Otsu M; Nakauchi H; Koeffler HP; Sanada M
Clin Cancer Res; 2010 Aug; 16(15):3825-31. PubMed ID: 20547695
[TBL] [Abstract][Full Text] [Related]
13. Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.
Bacher U; Haferlach C; Schnittger S; Kohlmann A; Kern W; Haferlach T
Ann Hematol; 2010 Jul; 89(7):643-52. PubMed ID: 20195608
[TBL] [Abstract][Full Text] [Related]
14. A novel, germline, deactivating CBL variant p.L493F alters domain orientation and is associated with multiple childhood cancers.
Norris GA; Tsai AC; Schneider KW; Wu YH; Caulfield T; Green AL
Cancer Genet; 2021 Jun; 254-255():18-24. PubMed ID: 33550024
[TBL] [Abstract][Full Text] [Related]
15. Juvenile myelomonocytic leukemia due to a germline CBL Y371C mutation: 35-year follow-up of a large family.
Pathak A; Pemov A; McMaster ML; Dewan R; Ravichandran S; Pak E; Dutra A; Lee HJ; Vogt A; Zhang X; Yeager M; Anderson S; Kirby M; ; ; Caporaso N; Greene MH; Goldin LR; Stewart DR
Hum Genet; 2015 Jul; 134(7):775-87. PubMed ID: 25939664
[TBL] [Abstract][Full Text] [Related]
16. Embryonal rhabdomyosarcoma in a patient with a germline CBL pathogenic variant.
Ji J; Navid F; Hiemenz MC; Kaneko M; Zhou S; Saitta SC; Biegel JA
Cancer Genet; 2019 Feb; 231-232():62-66. PubMed ID: 30803559
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
